Molson Coors Beverage Company vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Chicago global brewer (NYSE: TAP) ~$11.7B FY2024 revenue; Coors Light/Miller Lite Bud Light boycott beneficiaries, Coors Banquet cultural renaissance, premiumization competing with ABI and Constellation.
About
Molson Coors Beverage Company is a Chicago, Illinois-based global brewer and beverage company — publicly traded on the New York Stock Exchange (NYSE: TAP) as an S&P 500 Consumer Staples component — brewing and selling beer and flavored beverages through iconic brands including Coors Light, Miller Lite, Coors Banquet, Blue Moon, Molson Canadian, Carling, and hard seltzers through approximately 17,000 employees in over 30 countries. In fiscal year 2024, Molson Coors reported net sales of approximately $11.7 billion with underlying pretax income growth driven by premiumization mix shift and cost management, as the company continued executing its Revitalization Plan to grow net sales per hectoliter through premium brand investment and above-premium portfolio expansion. CEO Gavin Hattersley's strategy capitalized on the 2023 Bud Light controversy — Anheuser-Busch InBev's Dylan Mulvaney partnership backlash triggered a historic consumer boycott that shifted an estimated 2-3 share points of mainstream US beer volume from Bud Light to Coors Light and Miller Lite in 2023-2024 — representing the largest beer market share shift in decades, as Molson Coors brands became the beneficiary of Bud Light's largest-ever US sales decline. Molson Coors accelerated above-premium brand investment (Peroni Nastro Azzurro, Blue Moon LightSky, Simply Hard Lemonade partnership with Coca-Cola) to capture volume shift at higher margin price points while the two mainstream brands (Coors Light and Miller Lite) absorbed the incremental mainstream volume from Bud Light share loss.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.